Market Cap : 41.77 B | Enterprise Value : 43.49 B | PE Ratio : 14.77 | PB Ratio : 3.27 |
---|
BIIB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIIB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Biogen's Average Total Inventories for the quarter that ended in Sep. 2022 was $1,335 Mil. Biogen's Revenue for the three months ended in Sep. 2022 was $2,509 Mil. Biogen's Inventory-to-Revenue for the quarter that ended in Sep. 2022 was 0.53.
Biogen's Inventory-to-Revenue for the quarter that ended in Sep. 2022 increased from Jun. 2022 (0.49) to Jun. 2022 (0.53)
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueDays Inventory indicates the number of days of goods in sales that a company has in the inventory. Biogen's Days Inventory for the three months ended in Sep. 2022 was 259.39.
Inventory Turnover measures how fast the company turns over its inventory within a year. Biogen's Inventory Turnover for the quarter that ended in Sep. 2022 was 0.35.
The historical data trend for Biogen's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Biogen's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Biogen's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Biogen's Inventory-to-Revenue falls in comparison to its industry or sector. The grey bar indicates the Inventory-to-Revenue's extreme value range as defined by GuruFocus.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Biogen's Inventory-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as
Inventory-to-Revenue (A: Dec. 2021 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (A: Dec. 2020 ) | + | Total Inventories (A: Dec. 2021 )) | / | count ) | / | Revenue (A: Dec. 2021 ) |
= | ( (1068.6 | + | 1351.5) | / | 2 ) | / | 10981.7 |
= | 1210.05 | / | 10981.7 | ||||
= | 0.11 |
Biogen's Inventory-to-Revenue for the quarter that ended in Sep. 2022 is calculated as
Inventory-to-Revenue (Q: Sep. 2022 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (Q: Jun. 2022 ) | + | Total Inventories (Q: Sep. 2022 )) | / | count ) | / | Revenue (Q: Sep. 2022 ) |
= | ( (1294.2 | + | 1375) | / | 2 ) | / | 2508.5 |
= | 1334.6 | / | 2508.5 | ||||
= | 0.53 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueLikewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenueMore Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Biogen's Days Inventory for the three months ended in Sep. 2022 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Sep. 2022 ) | / | Cost of Goods Sold (Q: Sep. 2022 ) | * | Days in Period |
= | 1334.6 | / | 469.5 | * | 365 / 4 | |
= | 259.39 |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Biogen's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Sep. 2022 ) | / | Average Total Inventories (Q: Sep. 2022 ) |
= | 469.5 | / | 1334.6 | |
= | 0.35 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Biogen's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Murphy Nicole | officer: Head of Pharm Ops and Tech | BIOGEN INC. 225 BINNEY STREET CAMBRIDGE MA 02142 |
Izzar Rachid | officer: Head of Alzheimer's Disease | BIOGEN INC. 225 BINNEY STREET CAMBRIDGE MA 02142 |
Jones William D /ca/ | director | |
Freire Maria C | director | C/O ALEXANDRIA REAL ESTATE EQUITIES, INC 26 NORTH EUCLID AVENUE PASADENA CA 91101 |
Mcdonnell Michael R | officer: EVP, Chief Financial Officer | C/O IQVIA HOLDINGS INC. 83 WOOSTER HEIGHTS ROAD DANBURY CT 06810 |
Galdes Alphonse | officer: EVP Pharmaceutical Oper & Tech | BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
Hawkins William A | director | MEDTRONIC INC 710 MEDTRONIC PKWY, MS LC310 MINNEAPOLIS MN 55432-5604 |
Mantas Jesus B | director | BIOGEN INC. 225 BINNEY STREET CAMBRIDGE MA 02142 |
Kramer Robin | officer: VP, Chief Accounting Officer | 999 VANDERBILT BEACH ROAD 3RD FLOOR NAPLES FL 34109 |
Karp Daniel | officer: EVP, Corporate Development | 225 BINNEY STREET CAMBRIDGE MA 02142 |
Capello Jeffrey D | officer: EVP & Chief Financial Officer | BOSTON SCIENTIFIC CORPORATION ONE BOSTON SCIENTIFIC PLACE NATICK MA 01760 |
Guindo Chirfi | officer: EVP Glob. Mkt Acc & Cust Innov | C/O BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
Gregory Ginger | officer: EVP, Human Resources | C/O BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
Kress Jean-paul | officer: EVP Pres Int'l & Global Hd GTO | 215 FIRST STREET, SUITE 415 CAMBRIDGE MA 02142 |
Mckenzie Paul | officer: EVP Pharmaceutical Oper & Tech | BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
From GuruFocus
By PRNewswire 03-04-2022
By PRNewswire 03-01-2022
By PRNewswire 03-09-2022
By GuruFocusNews 03-01-2022
By GuruFocusNews 04-04-2022
By GuruFocusNews 03-14-2022
By PRNewswire 03-04-2022
By GuruFocusNews 03-31-2022
Other Sources
By Zacks 2022-03-10
By Zacks 2022-03-14
By Fool 2022-02-23
By Zacks 2022-04-04
By Zacks 2022-02-17
By Zacks 2022-03-04
By Fool 2022-02-19
By Zacks 2022-03-01
By Zacks 2022-02-10
By Zacks 2022-03-30
By Zacks 2022-03-21
By Zacks 2022-03-10
By Zacks 2022-03-30
By tipranks.com 2022-02-21
By Seekingalpha 2022-03-07